
BioRestorative Therapies Inc (NASDAQ:BRTX) has selected the Center for Clinical Research in North Carolina as the company's second contract for its Phase 2 trial targeting chronic lumbar disc disease (cLDD).
BioRestorative develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.